Involvement of calcium regulating ion channels in contractility of human isolated urinary bladder

Jan Luptak¹, Michaela Kocmalova²,³, Sona Franova²,³, Juraj Sutovsky⁴, Marian Grendar³, Jan Sviha¹, Jan Kliment Sr¹, Robert Dusenka¹ and Martina Sutovska²,³

¹ Urology Clinic, Jessenius Faculty of Medicine, Martin University Hospital, Comenius University, Martin, Slovakia
² Department of Pharmacology, Martin’s Biomedical Center (BioMed), Jessenius Faculty of Medicine, Comenius University, Martin, Slovakia
³ Martin’s Biomedical Center (BioMed), Jessenius Faculty of Medicine, Comenius University, Martin, Slovakia
⁴ Neurosurgery Clinic, Jessenius Faculty of Medicine, Martin University Hospital, Comenius University, Martin, Slovakia

Abstract. This study specified the role of several key calcium-operating ion channels in contraction/relaxation of human detrusor muscle as possible target for overactive bladder (OAB) treatment. Detrusor samples, obtained from 18 males (average age 61.5 ± 5.9 years), were investigated by organ tissue bath method with following agents: diltiazem for L-type voltage-gated calcium channels; 3-fluropyridine-4-carboxylic acid (FPCA) for Orai-STIM channels; SKF 96365-hydrochloride for transient receptor potential (TRP) channels, T-type channels and Orai-STIM channels; 2-aminoethoxydiphenyl borate (2-APB) for inositol-triphosphate receptors (IP₃Rs) and Orai-STIM channels. Oxybutynin and mirabegron were tested under the same conditions as controls. Mirabegron, 2-APB and FPCA exhibited the best suppressive effect on carbachol-induced detrusor contractility. As expressed by area under the contractile curve (AUCC), 2-APB, FPCA and mirabegron have similar AUCC: 1.79, 1.73, 1.73. The highest AUCC was 3.64 for diltiazem+SKF, followed by 3.21 for diltiazem, 3.16 for SKF and 2.94 for oxybutynin. The lowest median amplitude and contraction variability is for 2-APB followed by mirabegron and FPCA. There were significant differences between: 2-APB/FPCA vs. diltiazem, diltiazem+SKF and SKF. Summary of results suggested the principal role of IP₃Rs, Orai-STIM coupling and large-conductance calcium-activated potassium channels in detrusor contraction and pointed on Orai-STIM channels as possible targets for OAB pharmacotherapy.

Key words: Overactive bladder — Smooth muscle — Calcium ion channels — Orai-STIM pathway — Organ tissue bath

Introduction

The relaxation of detrusor is mediated by tonic release of norepinephrine, which activates beta adrenergic receptors (β₃-ARs in human detrusor) and by intrinsic urinary bladder smooth muscle (UBSM) properties. The contraction is achieved by acetylcholine that activates UBSM muscarinic receptors (mainly M₃). Disturbances in these functions may result in lower urinary tract symptoms, such as urgency, frequency, and urge incontinence, the components of the overactive bladder syndrome (OAB) (Andersson 2015).

At the cellular level, delicate balance of mechanisms maintaining cytoplasmic calcium (Ca²⁺) levels is critical to normal detrusor function. Increases of intracellular Ca²⁺ resulting in contraction occur primarily due to extracellular Ca²⁺ entry through plasmalemmal ion channels or release of Ca²⁺ from the endoplasmic/sarcoplasmic reticulum (ER/SR) (Fig. 1). The propagation of UBSM action potential result from Ca²⁺ entry through L-type voltage-gated ion channels
The recent studies documented that M3 receptor-mediated detrusor contractions also require Ca2+ influx via L-type VGCC (Hedge 2006). Ca2+ influx through T-and L-type VGCC also determined the contractile status of UBSM, and, furthermore, T-type channel activity is important to maintain membrane potentials near the resting level (Sui et al. 2007). Nonselective cation channels such as transient receptor potential (TRP) channels significantly contribute on extracellular Ca2+ entry pathways in UBSM cells.

Although a number of intracellular organelles take up and release Ca2+, ER/SR represents the largest pool of releasable Ca2+ in smooth muscle cells. In response to a variety of stimuli Ca2+-release channels in the SR, namely ryanodine receptors (RyRs) and inositol-trisphosphate receptors (IP3Rs), mediate efflux of Ca2+ from the SR into the cytoplasm of the cell (Hill-Eubanks et al. 2011).

UBSM hyperactivity, such as OAB, can be successfully treated with muscarinic receptor antagonists (e.g. oxybutynin, tolterodine, fesoterodine or trospium) and
beta adrenergic receptor agonists (e.g. mirabegron). In addition to Ca\(^{2+}\) homeostasis, administration of both pharmacological groups influence transport of Ca\(^{2+}\) through plasma membrane or its release from SR. Mirabegron, β3-ARs agonist, represents a novel treatment strategy for overactive bladder. The canonical signaling pathway of β3-ARs is stimulation of adenyl cyclase to form cyclic adenosine 3’,5’-monophosphate (cAMP), resulting in activation of protein kinase A (PKA) which can suppress calcium-calmodulin-dependent myosin/actin interaction upon phosphorylation of myosin light chain kinase (Cernecka et al. 2015). Despite this, compelling evidence suggests that β3-ARs can also stimulate large-conductance calcium-activated potassium (BK\(^{2+}\)Ca) channels, e.g. in rodent (Hristov et al. 2008) and human bladder (Afeli et al. 2013) and this way indirectly inhibit L-type VGCC. On the other hand, the antimuscarinic agents inhibit processes triggered by activation of M3 receptors, especially emptying of Ca\(^{2+}\) from SR through the activation of IP3Rs. There is also the strong evidence that BK\(^{2+}\)Ca channel activity is inhibited upon M3 receptors activation and this mechanism contributes on suppressed UBSM contraction on administered antimuscarinics (Parajuli et al. 2016). Unlike IP3Rs, spontaneous RyRs-mediated Ca\(^{2+}\) release plays a negative role in UBSM activity by the activation of BK\(^{2+}\)Ca channels (Herrera and Nelson 2002).

However, recent possibilities of OAB pharmacotherapy have still several limitations. The patients may have a suboptimal response or antimuscarinic therapy is limited by associated compelling diagnosis or adverse events, e.g. dry mouth as the most common and altered cardiovascular and central nervous functions as the most severe adverse effects. According clinical trials, mirabegron was effective and well tolerated in patients with OAB (Khullar et al. 2013). However, preclinical safety data showed that mirabegron caused hepatotoxic, cardiovascular and CNS toxic adverse findings and thus drug is not suitable for all patients (Andersson 2015).

Extracellular Ca\(^{2+}\) influx in response to depletion of intracellular Ca\(^{2+}\) stores, a process termed store-operated Ca\(^{2+}\) entry (SOCE), is known to play an important role in a number of cell types. The ubiquitously expressed STIM proteins serve as SR Ca\(^{2+}\) sensors and members of the Orai family (Feske et al. 2016) of transmembrane proteins as the entities responsible for mediating Ca\(^{2+}\) entry. In response to a decrease in SR Ca\(^{2+}\) concentrations, STIM proteins aggregate to form discrete plasmalemmal-proximate clusters that tether and activate Orai proteins, thereby promoting extracellular Ca\(^{2+}\) entry. Outstanding morphological studies have shown that STIM and Orai family members are expressed in smooth muscle, and under the conditions tested, are capable of functionally coupling store depletion to extracellular Ca\(^{2+}\) entry (Hill-Eubanks et al. 2011).

The knowledge related to function of Orai-STIM-mediated Ca\(^{2+}\) entry is still limited. Orai-STIM pathway role was examined in rat model of OAB (Zhao et al. 2014), but not in human UBSM. The interpretation of data obtained in animal models may be complicated due to considerable species differences between human and animal detrusor regarding the relative contributions of Ca\(^{2+}\) influx (Wuest et al. 2007). Therefore, the aim of our in vitro experimental study was to specify role of Orai-STIM-mediated SOCE and other Ca\(^{2+}\)- regulating ion channels in contraction/relaxation of human UBSM. These results may enlarge knowledge and identify possible target for future treatment of OAB symptoms in patients that are not able to tolerate or do not response to classic drugs targeting muscarinic or adrenergic receptors.

### Material and Methods

#### Tissue samples

All processes were approved by the Institutional Ethics Committee of the Jessenius Faculty of Medicine, registered by the Institutional Review Board/Institutional Ethics Board Office (IRB 00005636), in accordance with Slovakian and European legislation (decision No. EK 1880/2016). Total 18 male patients (average age 61.5 ± 5.9 years) with localized prostate cancer (cT2N0M0), without OAB symptoms, were involved in current study. The following were exclusion criteria: severe systemic chronic disorders (rheumatologic, endocrine or cardiovascular), drugs influencing ion channels activity administered systemically (e.g. antiepileptics, antihypertensives or vasodilators), neurogenic bladder and/or inflammation of lower and upper urinary tract before operation. Patient recruitment was conducted by the provision of information sheets and written informed consent was obtained. Samples (20 × 15 × 10 mm) of UBSM were obtained from macroscopic healthy tissue at ventral bladder wall immediately after open radical retropubic prostatectomy at the Urologic Clinic, Jessenius Medical Faculty and Martin University Hospital by the cold knife technique. After removing, UBSM specimen was immersed into Krebs-Henseleit’s buffer of the following composition (nM): NaCl, 112.9; KCl, 4.7; CaCl\(_2\), 2.8; MgSO\(_4\), 0.5; NaHCO\(_3\), 24.9; and glucose, 11.1.

#### Chemicals

Oxybutynin, dimethyl sulfoxide (DMSO) and diltiazem hydrochloride were obtained from Sigma-Aldrich (Lambda life, Slovakia). 2APB, 3-fluoropyridine-4-carboxylic acid and SKF96365 were purchased from Tocris Bioscience (USA) and mirabegron was purchased from Astellas Pharma Inc. (Japan). All chemicals were dissolved in aqua pro injection except from 2APB, which was soluble in 10% DMSO.
**Isolated bladder smooth muscle contractile response under in vitro conditions**

From one tissue sample originated from particular patient were prepared 7 isolated UBSM strips. The contractility of these isolated UBSM samples was investigated by an organ tissue bath method that was well-described previously (Franova et al. 2009). Briefly, isolated UBSM strips (approximate size of each one 15 × 5 × 5 mm) were immediately placed into tissue bath chambers filled with Krebs-Henseleit’s buffer. The chambers were saturated by pneumoxide (95% O₂ + 5% CO₂) at a temperature of 36 ± 0.5°C and maintained at pH 7.5 ± 0.1. Carbachol at a concentration of 1 µM was used to induce initial contractions of all strips. The involvement of individual Ca²⁺-regulating ion channels in the amplitude of UBSM contractions was tested using their blockers at four different concentrations (1 μM, 10 μM, 100 μM and 1 mM) in Multi-Chamber Tissue Bath Systems (Experimetrics-ISO-09-TSZ8) equipped with ISO-SYS software. For comparative purposes, positive control drugs – oxybutynin and mirabegron were tested under the same conditions and at the same concentrations.

The following agents were used to influence Ca²⁺-regulating ion channels activity: i. 3-fluropyridine-4-carboxylic acid (FPCA), blocker of Orai1-STIM1- coupling; ii. Diltiazem (DIL), L-type VGCC channel blocker; iii. SKF 96365 hydrochloride (SKF), blocker of SOCE and K⁺ channels; iv. 2- aminoethoxydiphenyl borate (2APB), IP₃Rs, Orai and STIM1 antagonist; v. Diltiazem + SKF 96365 hydrochloride (DIL+SKF).

**Statistical analysis**

Statistical analysis was performed in R (R Core Team 2015) using libraries WRS2 (Mair et al. 2016) and car (Fox and Weisberg 2011). Normality of the data was assessed by quantile-quantile plots with bootstrap confidence intervals. Since the normalized amplitudes of contraction were not found Gaussian, the robust ANOVA was used for evaluation. Post-hoc confidence intervals were adjusted to control the family-wise error rate. Results with p-value below 0.05 were considered statistically significant. For each chemical, the median normalized amplitudes of contraction was computed, and expressed as percentage of the median for carbachol. For resulting contractile curves the Area Under the Contractile Curve (AUCC) was computed by Simpson’s rule using the library Bolstad2 (Curran and Bolstad 2013).

**Results**

The lower ability in suppression of carbachol-induced UBSM amplitude of contraction was evidenced on increasing doses

---

**Figure 2.** Normalized median of amplitude of contraction, expressed as % of an initial tension induced by carbachol (c = 1 µM) measured as a response on administration of increased tested agents concentrations. The left bottom corner contains legend to figure with calculated area under the contractile curve for each followed agent.

**Figure 3.** The boxplot of amplitude of contraction (mN) computed for all used concentration of tested chemicals. Boxplot exhibits the first and third quartiles as the bottom and top of the box. The band inside the box is the median of a data, whiskers indicating variability outside the upper and lower quartiles. Outliers may be plotted as individual points. For abbreviations explanation, see also legend to Fig. 1.
of SKF, DIL, SKF+DIL and also positive control drug oxybutynin. In addition, mirabegron, 2APB and FPCA exhibited better suppressive effect on isolated UBSM contractility induced by muscarinic receptors stimulation. As expressed by AUCC, the highest AUCC was 3.64 for DIL+SKF; followed by 3.21 for DIL, 3.16 for SKF and 2.94 for oxybutynin. The other group comprised 2APB, FPCA, mirabegron, which have similar AUCC: 1.79, 1.73, 1.73; respectively (Fig. 2).

Boxplot of the normalized amplitudes of contraction (in mN) for all considered chemicals is exhibited at Fig. 3. For a chemical, the boxplot exhibits the first and third quartiles as the bottom and top of the box. The band inside the box is the median of a data. The lowest median amplitude of contraction is in 2APB followed by mirabegron and DIL; the highest median is for SKF and SKF+DIL. Whiskers are those used in the Tukey boxplot. The data points above and below the whiskers can be considered outliers. The lowest variability in the amplitude of contraction can be observed for 2APB, mirabegron and FPCA; the highest for DIL (Fig. 3).

The robust ANOVA test rejected the equality of medians hypothesis ($p = 0.0017$). $p$-value and the 95% confidence interval for post-hoc tests are in Table 1. Judging by the non-adjusted $p$-values, there were statistically significant differences in the group medians of the normalized amplitudes of contraction between: 2APB and DIL; 2APB and DIL+SKF; 2APB and SKF; DIL and FPCA; FPCA and DIL+SKF; FPCA and SKF.

The FEW-adjusted 95% confidence interval permits making additional conclusions. The median normalized amplitude of contraction in 2APB is significantly lower than the median normalized amplitude of contraction of SKF. Similarly, the median normalized amplitude of contraction in FPCA is significantly lower than the median normalized amplitude of contraction of SKF (Table 1).

**Discussion**

In this study our attention was concerned on the Ca$^{2+}$ ion channels that are believed as the most important in contractile activity of UBSM: VGCC (L-type and T-type), IP$_3$ Rs and SOCE (TRPC superfamily and Orai-STIM channels). The in-

| Comparison of compounds | 1 mM | 10 μM | 1 μM |
|-------------------------|------|-------|------|
|                         | lower CI | upper CI | p   | lower CI | upper CI | p   | lower CI | upper CI | p   |
| 2APB vs. OXY            | -2.73  | 0.98   | 0.09 | -2.68   | 0.86    | 0.07 | -2.66   | 0.72    | 0.05* |
| 2APB vs. DIL            | -1.70  | 0.42   | 0.04*| -1.68   | 0.31    | 0.02*| -1.68   | 0.18    | 0.01* |
| 2APB vs. FPCA           | -0.44  | 0.43   | 0.09 | -0.70   | 0.57    | 0.71 | -0.77   | 0.63    | 0.73  |
| 2APB vs. MIR            | -1.15  | 0.46   | 0.13 | -1.20   | 0.35    | 0.06 | -1.31   | 0.31    | 0.04* |
| 2APB vs. SKF+DIL        | -2.42  | 0.47   | 0.02*| -2.72   | 0.48    | 0.02*| -2.81   | 0.33    | 0.01* |
| 2APB vs. SKF+DIL        | -2.42  | -0.13  | 0.002*| -3.21   | -0.22   | 0.008*| -3.49   | 0.33    | 0.01* |
| OXY vs. DIL             | -1.67  | 2.14   | 0.65 | -1.59   | 2.04    | 0.65 | -1.60   | 1.96    | 0.71  |
| OXY vs. SKF             | -0.97  | 2.74   | 0.09 | -0.93   | 2.61    | 0.09 | -0.89   | 2.62    | 0.08  |
| OXY vs. MIR             | -1.33  | 2.39   | 0.29 | -1.30   | 2.26    | 0.32 | -1.33   | 2.19    | 0.37  |
| OXY vs. SKF+DIL         | -2.18  | 1.92   | 0.86 | -2.68   | 1.51    | 0.33 | -2.31   | 1.94    | 0.59  |
| OXY vs. SKF             | -2.32  | 1.52   | 0.45 | -0.41   | 1.64    | 0.04*| -2.85   | 1.55    | 0.31  |
| DIL vs. FPCA            | -0.42  | 1.70   | 0.04*| -0.82   | 1.33    | 0.40 | -0.30   | 1.67    | 0.03* |
| DIL vs. MIR             | -0.85  | 1.44   | 0.36 | -2.68   | 0.86    | 0.07 | -0.79   | 1.29    | 0.40  |
| DIL vs. SKF+DIL         | -1.88  | 1.21   | 0.45 | -1.68   | 0.31    | 0.02*| -2.10   | 1.12    | 0.28  |
| DIL vs. SKF             | -1.97  | 0.69   | 0.11 | -2.09   | 1.22    | 0.35 | -2.76   | 1.10    | 0.13  |
| FPCA vs. MIR            | -1.14  | 0.45   | 0.12 | -2.57   | 0.95    | 0.11 | -1.32   | 0.46    | 0.11  |
| FPCA vs. SKF             | -2.42  | 0.47   | 0.02*| -2.66   | 0.54    | 0.03*| -2.75   | 0.41    | 0.02* |
| MIR vs. SKF+DIL         | -2.10  | 0.85   | 0.14 | -2.31   | 0.92    | 0.13 | -2.33   | 0.85    | 0.11  |
| MIR vs. SKF             | -2.15  | 0.28   | 0.01*| -2.79   | 0.66    | 0.04*| -2.99   | 0.83    | 0.05* |
| SKF+DIL vs. SKF         | -1.89  | 1.28   | 0.5  | -2.37   | 1.6     | 0.51 | -2.45   | 1.77    | 0.57  |

Statistically significant data are marked by *.

2APB, 2-aminoethoxydiphenyl borate; OXY, oxybutynin; DIL, diltiazem; FPCA, 3-fluro-pyridine-4-carboxylic acid; MIR, mirabegron; SKF, SKF 96365-hydrochloride.

Table 1. $p$-value (calculated using robust ANOVA) and the 95% confidence interval (CI) for post-hoc test evaluated by comparison of individual compounds.
dividual ion channels activity was modulated by DIL, FPCA, SKF and 2APB and organ tissue bath method was selected for evaluation. UBSM strips have been employed over the years by many groups to answer a number of scientific questions, including examination of the effects of drugs that modulate smooth muscle tone with the aim of discovering ion channels and/or receptors and/or intracellular pathways that could be targeted to induce either relaxation or contraction (Kullmann et al. 2014). This relatively simple in vitro method was used to discover and test compounds currently used for OAB management (Svalø et al. 2013). As it is distinct from clinical trials, M3 antimuscarinics and agonists of β3-ARs possess relatively reliable effect; however, such treatment has several significant limitation; e.g. antimuscarinic side effects or cardiotoxicity and CNS toxicity resulting from adrenergic stimulation. Oxybutynin and mirabegron were selected as positive control drugs in this study. We confirmed that antimuscarinic drug oxybutynin and β3AR agonist mirabegron effectively and dose-dependently decreased amplitude of carbachol-induced contraction in isolated UBSM. Our results did not evidence any significant differences in the effectiveness between both agents. According to molecular mechanisms involved in oxybutynin and mirabegron mechanism of action, it is distinct that UBSM contractile activity is significantly regulated especially by Ca2+ and K+ ion channels.

DIL is a non-dihydropyridine L-type VGCC blocker used in the treatment of hypertension, angina pectoris, and some types of cardiac arrhythmia. FPCA dose-dependently inhibits Orai1-STIM1 coupling (Whitten et al. 2011). SKF is an imidazole compound 1-[(β-cyclohexylmethyl)[β-(4-methoxyphenyl) propoxy]-4-methoxyphenethyl]-1H-imidazole hydrochloride. SKF effect rests with used concentration: at c = 1–10 μM this agent inhibits T-type VGCC, from c = 10 μM blocks also TRPC (Singh et al. 2010), K+ATP and BK⁺Ca channels; and prevents Orai1-STIM1 coupling in dose-dependent manner (Tanahashi et al. 2016). 2APB was originally described as an IP3 Rs antagonist and was later shown to inhibit SOCE and ICrAC dose-dependently, independently of IP3 Rs inhibition. 2APB effect is related to concentration. 2APB at low concentrations (c = 1 μM and 10 μM) inhibits IP3 Rs, while it's higher concentrations (c = 100 μM and 1 mM) are able to block Orai and STIM1 structure (Orai1>>STIM1>>Orai2, Orai3) (DeHaven et al. 2008).

The lower (1 μM and 10 μM) and higher (100 μM and 1 mM) used concentrations of tested agents allowed to mutually compare the involvement of the different Ca²⁺ sources in human isolated carbachol-induced UBSM contraction (for further explanation see Fig. 1).

At lower used concentrations of tested modulators, the results confirmed the most significant relaxing effect of 2APB, FPCA and mirabegron. This indicated essential role of Ca²⁺ released from internal sources upon IP3 Rs activation and Ca²⁺-induced Ca²⁺ release in human UBSM contraction. The release of Ca²⁺-mediated by IP3 Rs activation is generally accepted as a principal mechanism in M3 receptors mediated detrusor activity. Furthermore, it was showed that 2APB possessed significantly better suppressive effect than antimuscarinic drug oxybutynin, despite that both in essence inhibited the same target – release of Ca²⁺ through IP3Rs. As it was recently reported that muscarinic receptor induced contractions of the detrusor (and also effect of oxybutynin) is mediated not only by IP3 Rs but partially also by TRPC4β channels (Griffin et al. 2016). The suppression of carbachol-induced UBSM contraction similar to 2APB was observed on mirabegron. Cernecka et al. (2015) reported similar data and confirmed a significant contribution of BK⁺Ca channels in β3AR-mediated human UBSM relaxation after precontraction with carbachol. Thus, in human UBSM cells BK⁺Ca channel outward currents have been shown to be a major determinant of repolarization following action potentials (Bentzen et al. 2014). The lower importance of Ca²⁺ transported though TRPC and VGCC (both T-type and L-type) than release of Ca²⁺ from ER in carbachol-induced contraction of isolated human UBSM was clear from significant differences between SKF and 2APB, DIL and 2APB or SKF+DIL and 2APB effects. This corresponded with Wuest et al. (2007) revealed that block of L-type VGCC with nifedipine impaired carbachol-induced contractions markedly less in human than in animal detrusor. Howbeit the role of ER Ca²⁺ stores and SOCE in various smooth muscle types was noticeably studied within previous two decades suggested significant involvement of Orai-STIM pathway and TRPC in control of smooth muscle contractile activity (Wang et al. 2008); only Zhao et al. (2014) experimental study in rats confirmed the role of SOCE in UBSM. Our study, for the first time, pointed on this mechanism as an important regulator of UBSM contractility. At higher used concentrations of tested agents, FPCA relaxing effect was comparable to 2APB and mirabegron and both Orai-STIM pathway inhibitors possessed significantly higher suppressive activity than SKF. As it was reported only recently, SKF in such concentrations inhibited not only Orai-STIM coupling but also BK⁺Ca and K⁺ATP channels (Tanahashi et al. 2016).

Several studies investigated UBSM contractility confirmed changes in contractile response of subjects with bladder outflow obstruction and in effect of UBSM relaxing drugs (Svalø et al. 2013; Zhao et al. 2014) and proposed alteration in ion channels expression/activity as the main reason of this finding. Aydin et al. (2012) demonstrated an approximate 5-fold decrease in bladder myocytes BK⁺Ca activity that may enhance basal and nerve-mediated UBSM contractility, leading to bladder overactivity and urinary incontinence (Meredith et al. 2004). In addition, Ca²⁺ ions that activate BK⁺Ca channels are released from RyRs, which expression decreased in detrusor instability (Jiang et al. 2005). The balance between T-type and L-type Ca²⁺
currents is altered in myocytes from overactive human bladders, with the T-type component proportionately increased and slightly significantly decreased L-type current (Sui et al. 2007). This contributed on increased incidence of intracellular Ca\(^{2+}\) transients and spontaneous action potentials in cells from OAB. Zhao et al. (2014) revealed significant variations in muscle contraction when compared effect of SOCE activator and inhibitor (SKF 96365) in healthy rats and the animals with experimentally-induced detrusor overactivity, suggested changes in expression of Orai-STIM pathway activators. All pathological changes in OAB related to ion channels activity/expression can possibly alter the response on classic treatment. We consider that targeting of Orai or STIM by tissue-selective inhibitors would produce detrusor-specific effects on Ca\(^{2+}\) dynamics. Nevertheless, there is still much to be learned about the interactions among and influence of the many components that regulate intracellular Ca\(^{2+}\) in UBSM and further research in this area is warranted.

In conclusion, the present results confirmed, for the first time, that SOCE involving Orai-STIM pathway plays an important role in human isolated UBSM contractile activity. Inhibition of Orai-STIM channels would prevent Ca\(^{2+}\) overload state that would lead to overstimulation of RyRs and IP\(_3\)Rs from their luminal sides and thus the enhanced spontaneous activity, as it has been reported for cardiac muscle (Stultzmann and Mattson 2011). In this study the inhibition of Orai-STIM pathway produced suppressive effect on UBSM carbachol-induced contraction similar to effect seen on inhibition of IP\(_3\)Rs by 2APB or activation of β3–cAMP – BK\(^{\text{Ca}}\) pathway by mirabegron. Orai-STIM channels may represent novel therapeutic targets for OAB pharmacotherapy. Future studies focused on their role in patients with OAB are warranted. The potential clinical application of Orai-STIM modulation for OAB therapy should be further validated in clinical trials.

Acknowledgement. The authors acknowledge Katarina Jesenškova for her outstanding technical assistance during experimental works. This study was supported by the project “BioMed” ITMS 26220220187 co-financed from EC sources, grants UK/57/2017 and VEGA No. 1/0062/11, 1/0127/13 and 1/0163/16.

Conflict of interest. The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

Afeli SAY, Rovner ES, Petkov GV (2013): BRL37344, a β3-adrenergic receptor agonist, decreases nerve-evoked contractions in human detrusor smooth muscle isolated strips: role of BK channels. Urology 82, e1–e7

https://doi.org/10.1016/j.urology.2013.05.027

Andersson KE (2015): Drug therapy of overactive bladder – What is coming next? Korean J. Urol. 56, 673–679

https://doi.org/10.4111/kju.2015.56.10.673

Aydin M, Wang HZ, Zhang X, Chua R, Downing K, Melman A, DiSanto ME (2012): Large-conductance calcium-activated potassium channel activity, as determined by whole-cell patch clamp recording, is decreased in urinary bladder smooth muscle cells from male rats with partial urethral obstruction. BJU International. 110, E402–E408

https://doi.org/10.1111/j.1464-410X.2012.11137.x

Bentzen BH, Olesen S-P, Rønn LCB, Grunnet M (2014): BK channel activators and their therapeutic perspectives. Front. Physiol. 5, 389

https://doi.org/10.3389/fphys.2014.00389

Cernecka H, Kersten K, Maarsingh H, Elzinga CR, de Jong IJ, Korstanje C, Michel MC, Schmidt M (2015): β3-Adrenoceptor-mediated relaxation of rat and human urinary bladder: roles of BKCa channels and Rho kinase. Naunyn Schmiedebergs Arch. Pharmacol. 388, 749–759

https://doi.org/10.1007/s00210-015-1128-z

Curran J, Bolstad W (2013): Bolstad: Bolstad functions. R package version 1.0-28, https://CRAN.R-project.org/package=Bolstad2

DeHaven WI, Smyth JT, Boyles RR, Bird GS, Putney JW Jr (2008): Complex actions of 2-aminoethylphosphoryl borate on store-operated calcium entry. J. Biol. Chem. 283, 19265

https://doi.org/10.1074/jbc.M801535200

Feske S, Gwack Y, Prakriya M, Srikanth S, Puppel SH, Tanasa B, Hogan PG, Lewis RS, Daly M, Rao A (2016): A mutation in Orai1 causes immune deficiency by abrogating CRAC channel function. Nature 441, 179–185

https://doi.org/10.1038/nature04702

Franova S, Janíček F, Visnovský J, Dokus K, Zubor P, Sutovska M, Nosalova G (2009): Utero-relaxant effect of PDE4-selective inhibitor alone and in simultaneous administration with β2-mimetic on oxytocin-induced contractions in pregnant myometrium. J. Obstet. Gynaecol. Res. 35, 20–25

https://doi.org/10.1111/j.1477-0527.2008.00839.x

Fox J, Weissberg S (2011): An R Companion to Applied Regression. Second Edition. Thousand Oaks CA, Sage

Griffin CS, Bradley E, Dudem S, Hollywood MA, McHale NG, Thornbury KD, Sergeant GP (2016): Muscarinic receptor-induced contractions of the detrusor are mediated by activation of TRPC4 channels. J. Urol. 196, 1796–1808

https://doi.org/10.1016/j.juro.2016.05.108

Hedge SS (2006): Muscarinic receptors in the bladder: from basic research to therapeutics. Br. J. Pharmacol. 147, S80–S87

https://doi.org/10.1038/sj.bjp.0706560

Herrera GM, Nelson MT (2002): Differential regulation of SK and BK channels by Ca(2+)/signals from Ca(2+)/channels and ryanodine receptors in guinea-pig urinary bladder myocytes. J. Physiol. 541, 483–492

https://doi.org/10.1111/j.physiol.2002.017707

Hill-Eubanks DC, Werner ME, Heppner TJ, Nelson MT (2011): Calcium signaling in smooth muscle. Cold Spring Harb. Perspect. Biol. 3, a004549

https://doi.org/10.1101/cshperspect.a004549

Hristov KL, Cui X, Brown SM, Liu L, Kellett WF, Petkov GV (2008): Stimulation of β3-adrenoceptors relaxes rat urinary bladder. Urology 72, 688–694

https://doi.org/10.1016/j.urology.2007.11.033
bladder smooth muscle via activation of the large-conductance Ca2+-activated K+ channels. Am. J. Physiol. Cell Physiol. 295, C1344–C1353 https://doi.org/10.1152/ajpcell.00001.2008

Jiang HH, Song B, Lu GS, Wen QJ, Jin XY (2005): Loss of ryanodine receptor calcium-release channel expression associated with overactive urinary bladder smooth muscle contractions in a detrusor instability model. BJU International. 96, 428–433 https://doi.org/10.1111/j.1464-410X.2005.05644.x

Khullar V, Amarenco G, Angulo JC, Cambronero J, Hoyle K, Milson I, Radziszewski P, Rechberger T, Boerrigter P, Drogendijk T, et al. (2013): Efficacy and tolerability of mirabegron, a β3-adrenoreceptor agonist, in patients with overactive bladder: results from a randomised european-australian phase3 Trial. Eur. Urol. 63, 283–295 https://doi.org/10.1016/j.euro.2012.10.016

Kullmann FA, Daugherty SL, de Groat WC, Birder LA (2014): Bladder smooth muscle strip contractility as a method to evaluate lower urinary tract pharmacology. J. Vis. Exp. 90, e51807 https://doi.org/10.3791/51807

Mair P, Schoenbrodt F, Wilcox R (2016): WRS2: Wilcox robust estimation and testing (R package Version 0.9.1) [Software package] https://cran.r-project.org/web/packages/WRS2/

Mair P, Schoenbrodt F, Wilcox R (2016): WRS2: Wilcox robust estimation and testing (R package Version 0.9.1) [Software package] https://cran.r-project.org/web/packages/WRS2/

Parajuli SP, Zheng Y-M, Levin R, Wang Y-X (2016): Big-conductance Ca2+-activated K+ channels in physiological and pathological urinary bladder smooth muscle cells. Channels 10, 355–364 https://doi.org/10.1080/19336950.2016.1180488

R Core Team (2015): R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria

Singh A, Hildebrand M, Garcia E, Snutch T (2010): The transient receptor potential channel antagonist SKF96365 is a potent blocker of low-voltage-activated T-type calcium channels. Br. J. Pharmacol. 160, 1464–1475 https://doi.org/10.1111/j.1476-5381.2010.00786.x

Svalø J, Nordling J, Bouchelouche K, Andersson KE, Korstanje C, Bouchelouche P (2013): The novel β3-adrenoceptor agonist mirabegron reduces carbachol-induced contractile activity in detrusor tissue from patients with bladder outflow obstruction with or without detrusor overactivity. Eur. J. Pharmacol. 699, 101–105 https://doi.org/10.1016/j.ejphar.2012.11.060

Stutzmann GE, Mattson MP (2011): Endoplasmic reticulum Ca2+ handling in excitable cells in health and disease. Pharmacol. Rev. 63, 700–727 https://doi.org/10.1124/pr.110.003814

Sui GP, Wu C, Severs N, Newgreen D, Fry CH (2007): The association between T-type Ca2+ current and outward current in isolated human detrusor cells from stable and overactive bladders. BJU International. 99, 436–441 https://doi.org/10.1111/j.1464-410X.2006.06568.x

Tanahashi Y, Wang B, Murakami Y, Unno T, Matsuyama H, Nagano H, Komori S (2016): Inhibitory effects of SKF96365 on the activities of K+ channels in mouse small intestinal smooth muscle cells. J. Vet. Med. Sci. 78, 203–211 https://doi.org/10.1292/jvms.15-0346

Wang Y, Deng X, Hewavitharana T, Soboloff J, Gill DL (2008): STIM, Orai and TRPC channels in the control of calcium entry signals in smooth muscle. Clin. Exp. Pharm. Physiol. 35, 1127–1133 https://doi.org/10.1111/j.1440-1681.2008.05018.x

Whitten JP, Pei J, Cao J, Wang Z, Rogers E, Dyck B, Grey J (2011): Compounds that modulate intracellular calcium. US patent No. WO/2011/139765

Wuest M, Hiller N, Braeter M, Hakenberg OW, Wirth MP, Ravens U (2007): Contribution of Ca2+ influx to carbachol-induced detrusor contraction is different in human urinary bladder compared to pig and mouse. Eur. J. Pharmacol. 565, 180–189 https://doi.org/10.1016/j.ejphar.2007.02.046

Zhao B, Zhong X, Bai X, Wang Q, Song B, Li L (2014): Changes in store-operated calcium channels in rat bladders with detrusor overactivity. Urology 84, 491.e1–6 https://doi.org/10.1016/j.urology.2014.05.007

Received: October 10, 2017
Final version accepted: December 4, 2017
First published online: June 29, 2018